Shandong Weigao Group Medical Polymer 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rinan Cong

최고 경영자

CN¥4.0m

총 보상

CEO 급여 비율	42.1%
CEO 임기	no data
CEO 소유권	0.05%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Rinan Cong 의 보수는 Shandong Weigao Group Medical Polymer 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥4m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥5m	CN¥950k	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥3m	CN¥903k	CN¥2b

보상 대 시장: Rinan 의 총 보상 ($USD 546.72K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 471.06K ).

보상과 수익: Rinan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rinan Cong (43 yo)

no data

테뉴어

CN¥3,990,000

보상

Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jing Long	Executive Chairman of the Board & Compliance Officer	6yrs	CN¥8.27m	0.14% HK$ 29.7m
Rinan Cong	Chief Executive Officer	no data	CN¥3.99m	0.048% HK$ 10.1m
Junqiang Lu	Executive Director	2.5yrs	CN¥1.32m	데이터 없음
Xue Feng Wu	Chief Financial Officer	7.8yrs	데이터 없음	데이터 없음
Xia Yan	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Daoming Wang	Executive Director	less than a year	데이터 없음	0.011% HK$ 2.3m
Miu Ling Wong	Company Secretary	18.6yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 1066 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jing Long	Executive Chairman of the Board & Compliance Officer	6yrs	CN¥8.27m	0.14% HK$ 29.7m
Junqiang Lu	Executive Director	2.5yrs	CN¥1.32m	데이터 없음
Xia Yan	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Daoming Wang	Executive Director	less than a year	데이터 없음	0.011% HK$ 2.3m
Lin Chen	Non-Executive Director	3.8yrs	데이터 없음	데이터 없음
Hong Meng	Independent Non-Executive Director	2.3yrs	CN¥150.00k	데이터 없음
Guohui Li	Independent Non-Executive Director	2.5yrs	CN¥207.00k	데이터 없음
Zhengpeng Tang	Vice Chairman	3.8yrs	데이터 없음	데이터 없음
Meijun Gu	Chairman of the Supervisors	4.4yrs	데이터 없음	데이터 없음
Zhuangqiu Zhang	Employee Representative Supervisor	2.7yrs	데이터 없음	데이터 없음
Qiang Li	Independent Non-Executive Director	2yrs	CN¥150.00k	데이터 없음
Heng Sun	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: 1066 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/25 15:34
장 마감 주가	2024/12/24 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Shandong Weigao Group Medical Polymer Company Limited 35 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jason Mann	Barclays
Derrick Sun	BNP Paribas Securities (Asia)
Feng Qiang Sun	BOCOM International Securities Limited

Shandong Weigao Group Medical Polymer 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Less than half of directors are independent

Recent updates

Shandong Weigao Group Medical Polymer Company Limited Approves the Distribution of Interim Dividend for the Six Months Ended 30 June 2024, Payable on 22 November 2024

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of CN¥0.092 per share

Investor sentiment improves as stock rises 16%

First half dividend of CN¥0.092 announced

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.27 in 1H 2023)

Shandong Weigao Group Medical Polymer Company Limited Proposes an Interim Dividend for the Six Months Ended 30 June 2024, Payable on Before 22 November 2024

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2024 Results on Aug 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Upcoming dividend of CN¥0.094 per share

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.61 in FY 2022)

Final dividend of CN¥0.094 announced

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.60 in FY 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Investor sentiment deteriorates as stock falls 18%

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Approves Distribution of Interim Dividend for the Six Months Ended 30 June 2023

Upcoming dividend of CN¥0.073 per share at 2.4% yield

First half 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 1H 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 24 November 2023

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued after recent price drop

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on or Before 14 July 2023

Upcoming dividend of CN¥0.079 per share at 1.5% yield

Full year 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.51 in FY 2021)

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Now 22% undervalued

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Resignation of Wang Jinxia as an Independent Non-Executive Director of the Company, A Member of Audit Committee, A Member of Remuneration Committee, A Member of Nomination Committee and A Member of Corporate Governance Committee

Now 20% undervalued

Shandong Weigao Group Medical Polymer Company Limited Approves Interim Dividend for the Six Months Ended June 30, 2022, Payable on November 11, 2022

Upcoming dividend of CN¥0.086 per share

Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066) agreed to acquire Weihai Weigao Medical Materials Company Limited from Weigao Holding Company Limited for approximately RMB288.0 million.

First half 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1H 2021)

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Changes

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2022 Results on Aug 22, 2022

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Executive Appointments

Upcoming dividend of CN¥0.065 per share

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.47 in FY 2020)

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Resignations

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, Jun 06, 2022

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2020)

Shandong Weigao Group Medical Polymer Company Limited Recommends Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited to Report Q4, 2021 Results on Mar 29, 2022

Upcoming dividend of CN¥0.077 per share

First half 2021 earnings released: EPS CN¥0.27 (vs CN¥0.22 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on May 24, 2021

Upcoming dividend of CN¥0.068 per share

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.41 in FY 2019)

Chairman & Compliance Officer Hua Wei Zhang has left the company

Executive Vice Chairman Yi Wang has left the company

Shandong Weigao Group Medical Polymer Company Limited Approves the Appointment of Tang Zheng Peng as a Non-Executive Director of the Company

New 90-day low: HK$13.28

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Chairman & Compliance Officer recently sold HK$14m worth of stock

New 90-day high: HK$17.06

Shandong Weigao Group Medical Polymer Company Limited Announces Director Changes

New 90-day low: HK$14.22

New 90-day low: HK$14.82